Neurizon Therapeutics Our Phase 1 clinical study has yielded positive results for patients with ALS, highlighting the safety, tolerability and potential for long-term efficacy of NUZ-001 (S-Monepantel) Trial patients have opted to continue treatment by enrolling in a 12-month open-label extension study
NUZ-001 shows positive early results, headed toward HEALEY trial NUZ-001 is an oral deworming agent commonly used in veterinary medicine It has an off-target effect of inhibiting mTOR signaling, which is involved in cell growth and the regulation of autophagy, a cellular process by which unneeded or damaged cellular components are broken down
Neurizons NUZ-001 Decreases TDP-43 Aggregation, a Key Target . . . Neurizon Therapeutics Limited (ASX: NUZ NUZOA), a biotech company focused on clinical developments for neurodegenerative conditions, is excited to report favorable outcomes from a preclinical evaluation of its primary candidate, NUZ-001